Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study.
Fiche publication
Date publication
janvier 2021
Journal
Annals of intensive care
Auteurs
Membres identifiés du Cancéropôle Est :
Pr OHANA Mickaël
Tous les auteurs :
Helms J, Severac F, Merdji H, Schenck M, Clere-Jehl R, Baldacini M, Ohana M, Grunebaum L, Castelain V, Anglés-Cano E, Sattler L, Meziani F,
Lien Pubmed
Résumé
Thromboprophylaxis of COVID-19 patients is a highly debated issue. We aimed to compare the occurrence of thrombotic/ischemic events in COVID-19 patients with acute respiratory distress syndrome (ARDS) treated with either prophylactic or therapeutic dosage of heparin. All patients referred for COVID-19 ARDS in two intensive care units (ICUs) from two centers of a French tertiary hospital were included in our cohort study. Patients were compared according to their anticoagulant treatment to evaluate the risk/benefit of prophylactic anticoagulation versus therapeutic anticoagulation. Medical history, symptoms, biological data and imaging were prospectively collected.
Mots clés
Anticoagulation, COVID-19, Coagulopathy, Pulmonary embolism, SARS-CoV-2, Thrombosis
Référence
Ann Intensive Care. 2021 Jan 25;11(1):14